Drugs / L-\[1-13C\]-phenylalanine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT06104527 Background | Oct 2023 → Mar 2026 | critical illness polyneuropathy, muscular atrophy | Maastricht University Medical Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-\[1-13C\]-phenylalanine | “An oral L-\[1-13C\]-phenylalanine tracer is given as co-intervention.” NCT06104527 ↗ |
| Route | Oral | “An oral L-\[1-13C\]-phenylalanine tracer is given as co-intervention.” NCT06104527 ↗ |